- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
24 result(s) found for: Monoamine oxidase inhibitors.
Displaying page 1 of 2.
EudraCT Number: 2006-005861-21 | Sponsor Protocol Number: NW-1015/018/III/2006 | Start Date*: 2007-06-11 | |||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS | |||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON TH... | |||||||||||||
Medical condition: Patients with idiopathic Parkinson's disease with motor fluctuations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004162-17 | Sponsor Protocol Number: A0501061 | Start Date*: 2015-03-24 |
Sponsor Name:Pfizer Inc | ||
Full Title: A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD) | ||
Medical condition: Post-Traumatic Stress Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-002500-91 | Sponsor Protocol Number: RPC01-3001 | Start Date*: 2015-10-12 | |||||||||||
Sponsor Name:Celgene International II Sàrl (CIS II) | |||||||||||||
Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003679-31 | Sponsor Protocol Number: 2015_22 | Start Date*: 2016-04-06 |
Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille | ||
Full Title: Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease | ||
Medical condition: De Novo Parkinson’s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Ongoing) CZ (Completed) PT (Completed) FR (Completed) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002855-41 | Sponsor Protocol Number: ANeED | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:Helse Fonna | |||||||||||||
Full Title: A phase IIa multicentre randomized controlled double blind clinical trial to demonstrate clinical efficacy on cognitive, neuropsychiatric and functional outcomes of Ambroxol in New and Early patien... | |||||||||||||
Medical condition: Dementia with Lewy Bodies (DLB) and mild cognitive impairment (MCI) due to Lewy Body Disease (DLB-MCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002571-24 | Sponsor Protocol Number: 15/0118 | Start Date*: 2016-10-14 |
Sponsor Name:Joint Research Office | ||
Full Title: A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Diseas... | ||
Medical condition: Parkinson disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004447-11 | Sponsor Protocol Number: VR040/2/008 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Vectura Limited | |||||||||||||
Full Title: A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe... | |||||||||||||
Medical condition: Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000914-21 | Sponsor Protocol Number: 161003 | Start Date*: 2012-02-13 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE A... | |||||||||||||
Medical condition: Mild to moderate Alzheimer’s disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005182-20 | Sponsor Protocol Number: S308.3.002 | Start Date*: 2007-02-13 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. | |||||||||||||
Medical condition: Advanced stage Parkinson's disease with motor fluctuations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001651-31 | Sponsor Protocol Number: 1.0 | Start Date*: 2017-11-30 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: EMPOWER: EMesis in Pregnancy - Ondansetron With mEtoclopRamide. | ||
Medical condition: Nausea and Vomiting in pregnancy Hyperemesis gravidarum | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003743-10 | Sponsor Protocol Number: BPL-003-201 | Start Date*: 2023-06-22 | |||||||||||
Sponsor Name:Beckley Psytech Ltd. | |||||||||||||
Full Title: A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression | |||||||||||||
Medical condition: Treatment-Resistant Depression (TRD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002840-26 | Sponsor Protocol Number: PD0005 | Start Date*: 2013-03-05 | |||||||||||
Sponsor Name:UCB Biosciences GmbH | |||||||||||||
Full Title: A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) HU (Completed) IT (Completed) BG (Completed) SI (Completed) RO (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005438-19 | Sponsor Protocol Number: SP882 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:SCHWARZ PHARMA Deutschland GmbH | |||||||||||||
Full Title: An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. | |||||||||||||
Medical condition: idiopathic Parkinson´s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017238-39 | Sponsor Protocol Number: IPX066-B09-06 | Start Date*: 2010-09-15 | |||||||||||
Sponsor Name:Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax) | |||||||||||||
Full Title: A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease | |||||||||||||
Medical condition: Idiopathic Parkinson’s Disease (paralysis agitans) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021394-37 | Sponsor Protocol Number: SP0976 | Start Date*: 2011-03-08 | |||||||||||
Sponsor Name:UCB Pharma SA | |||||||||||||
Full Title: MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BE (Completed) CZ (Completed) SK (Completed) ES (Completed) AT (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010193-38 | Sponsor Protocol Number: IPX066-B08-05 | Start Date*: 2009-06-02 | |||||||||||
Sponsor Name:IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc. | |||||||||||||
Full Title: A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease | |||||||||||||
Medical condition: Idiopathic Parkinson's disease (paralysis agitans) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003415-19 | Sponsor Protocol Number: JM-010CS03 | Start Date*: 2018-10-31 |
Sponsor Name:Contera Pharma | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Co... | ||
Medical condition: Parkinson’s Disease Patients With Moderate to Severe Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Restarted) IT (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000400-81 | Sponsor Protocol Number: S308.2.008 | Start Date*: 2009-04-03 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals BV | |||||||||||||
Full Title: A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s D... | |||||||||||||
Medical condition: Advanced Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000087-15 | Sponsor Protocol Number: BP39529 | Start Date*: 2017-12-21 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6... | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001095-36 | Sponsor Protocol Number: S308.3.004 | Start Date*: 2008-03-27 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals | |||||||||||||
Full Title: The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patient... | |||||||||||||
Medical condition: advanced stage of idiopathic PD with dose-dependent motor fluctuations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
